Hines DM, Shah S, Multani JK, et al. - Using IQVIA’s open‐source longitudinal pharmacy (LRx) and medical (Dx) claims databases, researchers conducted this retrospective longitudinal cohort study to characterize the patient features, adherence, and treatment patterns among adult migraine patients in the United States prescribed erenumab. Adult migraine patients with an initial claim (index date) for erenumab between May 1, 2018, and April 30, 2019 were identified, and study participants needed to have ≥ 180 days of follow‐up. The sample consisted of 64,174 patients. Nearly all patients had prior use of acute or preventive therapy. Erenumab adherence was better than that of traditional oral prophylactic migraine treatment, though overall adherence was still less than optimal. The decline in the use of acute and preventive prescription drugs after the introduction of erenumab indicates real-world efficacy.